一个单纯家族性嗜铬细胞瘤家系的VHL基因突变筛查

目的检测一个单纯家族性嗜铬细胞瘤家系的VHL基因突变情况。方法对一个单纯家族性嗜铬细胞瘤家系进行VHL基因突变检测，抽取该家系5例患者及15名血缘亲属外周血基因组DNA，对VHL基因3个外显子进行PCR，产物进行DNA测序。结果该家系5例患者均检测出VHL基因第2外显子上第587位核苷酸A—C突变，该突变导致第125位编码氨基酸由组氨酸（H）转变为脯氨酸（P）。15名家系成员中筛查出7名成员为该突变基因携带者，B超检查发现1例为双侧肾上腺肿瘤，1例为右肾囊肿。该突变为首次报道。结论该嗜铬细胞瘤家系中检测到可能的致病突变，VHL基因检测可早期发现致病基因携带者，建议对单纯家族性嗜铬细胞瘤患者常规进行VHL基因突变筛查。     

一多发性内分泌腺瘤病2A型家系的临床调查及基因分析

目的 进行一多发性内分泌腺瘤病2A型家系的临床调查及基因分析。方法 对一个包括先证者在内共24位成员的MEN2A家系进行临床调查,并提取16位成员外周血基因组DNA,对RET基因的第10、11外显子进行PCR扩增,PCR产物进行直接测序。结果 1、除先证者外该家系有1例患者,曾诊断MEN2A,但拒绝抽血检查;3例疑似患者,已死亡,无法进行基因分析;筛查出1名成员为基因突变携带者,后该成员于家中突发胸闷、面色苍白死亡; 2、经RET基因突变检查证实,该先证者及1名家系成员存在10q 11.2 外显子11 (密码子634 ) RET基因发生点突变：Cys634Arg。结论 本研究该家系存在外显子11的C634位点突变,应常规对所有MEN2A患者及其家系高危成员尽早进行基因突变分析和筛查。     

嗜铬细胞瘤分子遗传学研究进展

嗜铬细胞瘤分散发型和家族型两大类。近年来，家族型嗜铬细胞瘤的分子遗传学研究取得了重要进展，RET原癌基因突变和VHL基因的失活可能分别是MEN2和VHL病的致病因素。散发嗜铬细胞瘤发病的分子机制尚未阐明，可能涉及癌基因的激活，抑癌基因的缺失以及凋亡障碍和端粒酶活性增强等诸多因素。     

黑斑息肉综合征一家系中STK11基因突变研究

目的检测一个黑斑息肉综合征(PJS)家族的STK11基因突变类型。方法从PJS患者外周血及息肉组织中提取基因组DNA;采用PCR分别扩增STK11基因的9个外显子及非编码区域;采用直接测序法检测DNA序列;采用Western blot检测息肉组织中突变STK11蛋白表达情况。结果该家族中所有PJS患者在STK11基因第5个外显子21位密码子CAG突变为TAG,并编码截短了的STK11蛋白。结论 STK11基因第5个外显子21位密码子CAG突变为TAG是导致该家族PJS发病的原因,可作为该家族中预诊断PJS的指标,同时该突变也可能导致患者恶性肿瘤发生概率增加以及早期发病,提示PJS患者预后不良。     

Crouzon综合征基因突变检测

目的 研究1个Crouzon综合征家系及1例散发的Crouzon综合征患者的成纤维生长因子受体2(fibroblast growth factors receptor 2,FGFR2)基因突变情况.方法 在1个Crouzon综合征家系的10名成员,和另一例散发者的外周血提取基因组DNA,PCR扩增FGFR2基因的第8和10外显子(部分家族成员仅扩增第8外显子),产物纯化后直接进行DNA测序检测突变.结果 家系中3名成员及另1例散发者FGFR2基因第8外显子的833位核苷酸发生G→T的转换突变,该突变为错义突变,使该位点所编码的氨基酸由半胱氨酸变为苯丙氨酸(C278F).该突变为杂合子突变.结论 FGFR2基因突变是Crouzon综合征致病原因.     

嗜铬细胞瘤分子遗传学研究进展

嗜铬细胞瘤分散发型和家族型两大类。近年来 ,家族型嗜铬细胞瘤的分子遗传学研究取得了重要进展 ,RET原癌基因突变和 VHL 基因的失活可能分别是 MEN2和 VHL 病的致病因素。散发型嗜铬细胞瘤发病的分子机制尚未阐明 ,可能涉及癌基因的激活 ,抑癌基因的缺失以及凋亡障碍和端粒酶活性增强等诸多因素     

散发型嗜铬细胞瘤易感基因的热点区域的筛选

目的筛选与散发型嗜铬细胞瘤易感基因相关的染色体区域。方法收集北京协和医院2011年9月至2013年5月临床诊断的42例散发型嗜铬细胞瘤病例。提取嗜铬细胞瘤及外周血的基因组DNA,用Sanger测序法检测遗传型嗜铬细胞瘤的突变基因;在证实为散发型的部分病例中,用单核苷酸多态性芯片(SNP 6.0芯片)对其肿瘤组织及外周血的基因组进行扫描分析,精确定位可能的热点区域;然后以Q-PCR技术在其余的病例中进一步验证,从而最终确定散发型嗜铬细胞瘤相关的染色体片段。结果 38例散发型病例,4例遗传型病例。通过SNP 6.0芯片扫描发现染色体片段的缺失较扩增更为常见,缺失的染色体包括1p、3q、17p、22q和11p。1p上的chr1:74 957 006~86 132 879,chr1:58 096 424~67 700 471和chr1:98 902 091~107 622 4303个片段的缺失最为常见;Q-PCR验证后,上述3个片段仍为最常见的缺失区域。4例Ret突变者均出现上述3个片段的缺失。结论 1号染色体短臂的部分区域上可能存散发型嗜铬细胞瘤相关的抑癌基因。     

多发性骨骺发育不良患者软骨寡聚物基质蛋白基因新突变

目的 对1例多发性骨骺发育不良女性患者的软骨寡聚物基质蛋白(cartilage oligomeric matrix protein,COMP)基因进行突变分析,为遗传咨询和产前分子诊断提供指导.方法 采集患者血样,提取基因组DNA,用外显子序列捕获+第二代测序技术对COMP基因进行基因突变的检测并用聚合酶链反应结合Sanger法核苷酸序列测定进行突变位点验证.结果 该患者COMP基因第9外显子存在c.956A＞T错义突变,其COMP基因第319位密码子由原来编码天冬氨酸的密码子GAC突变为编码缬氨酸的密码子GTC(p.Asp319Val).SIFT功能预测该错义突变将影响蛋白结构.结论 该患者发病是由COMP基因c.956A＞T突变导致,该突变国内外未见报道.     

Apert综合征患儿FGFR2基因突变分析

目的研究Apert综合征患儿成纤维细胞生长因子受体2（FGFR2）基因突变以及临床特点。方法采集1例Apert综合征患儿及其父母的外周血,提取基因组DNA,应用PCR扩增FGFR2基因第7和第9外显子,对PCR产物进行双向测序检测基因突变。检索PubMed和中国知网数据库中相关文献进行系统分析。结果在患）LFGFR2基因的第7外显子的937碱基发生杂合突变,由c转变为G,导致FGFR2蛋白第253位密码子由脯氨酸变为精氨酸（P253w）,患儿父母均未检测到该基因突变。文献检索国内外已报道15例Apert综合征患儿,其中6例进行FGFR2基因突变分析,5例为S252W突变,1例为外显子Ⅲb／Ⅲc之间杂合缺失突变。结论该例hpert综合征患儿由FGFR2基因937C-G的杂合突变所致。     

一个中国人Liddle综合征家系的SCNN1G基因新突变及其临床特征

目的 分析2个Liddle综合征家系上皮细胞钠通道编码基因SCNN1B及SCNN1G的基因突变.方法 收集2个临床诊断为Liddle综合征的家系,抽取先证者及其家系成员外周血基因组DNA,PCR扩增上皮细胞钠通道β亚单位编码基因SCNN1B和γ亚单位编码基因SCNN1G第13外显子,产物直接DNA测序进行基因突变检测.结果 例1 SCNN1B基因第13外显子的扩增片段经双向测序显示第564密码子存在CGA-TGA(R-X)杂合无义突变,其家系成员均未发现这一基因突变;例2 SCNN1G基因第567密码子存在CAG-TAG(Q-X)杂合无义突变,2个家系成员携带此突变基因,这一突变位点尚未在国内外报道过,50名无关正常人中未发现此突变基因.结论 对临床诊断的Liddle综合征患者及其亲属,进行基因突变检测有助于确定诊断及早期筛查出家系中的其他患者.编码人类肾小管上皮细胞钠通道γ亚单位基因SCNN1G第13外显子第567密码子CAG-TAG(Q-X)杂合无义突变可能会导致Liddle综合征.     

Three novel mutations in the RET proto-oncogene

Medullary thyroid carcinoma (MTC) occurs as a sporadic tumor or in connection with inherited cancer syndromes of multiple endocrine neoplasia type 2 and familial MTC. Missense RET proto-oncogene mutations and small in-frame deletions are found in most of the cases. In a significant amount of sporadic MTC cases somatic mutation at codon 918 (exon 16), or at codons 609, 611, 618, 620 (exon 10), or codons 630, 634 (exon 11) appear. We report here on three new somatic cell missense mutations of the RET proto-oncogene associated with sporadic MTC. In one tumor mutation at codon 922 TCC(Ser)-->TTC(Phe) in exon 16 was found. In another tumor two mutations at codons 639 GCA(Ala)-->GGA(Gly) and 641 GCT(Ala)-->CGT(Arg) in the exon 11 were observed. Allele-specific PCR followed by sequencing demonstrated the presence of both mutations at the same allele.     

Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC: s

Since germllne mutations in the RET proto-oncogene (RET) predisposingto tumor development In Familial Medullary Thyroid Carcinoma(FMTC), Multiple endocrine neoplasia type 2A (MEN 2A), and Multipleendocrine neoplasia type 2B (MEN 2B) were reported, It has becomepossible to identify gene carriers with a very high degree ofaccuracy. Mutations in FMTC and MEN 2A exclusively affect cystelneresidues in exon 10 and 11 of RET, whereas in MEN 2B codon 918in exon 16 is involved. This latter mutation has also been describedin a subset of apparently sporadic medullary thyroid carcinomas(MTC). Mutations in MEN 2B often occur as de novo germline mutations,whereas de novo mutations have not yet been described In FMTCor MEN 2A. We analyzed ten MTC: s and ten pheochromocytomas,all clinically judged to be sporadically occurring, by directDNA sequencing of exons 10, 11, and 16 of RET. This analysisrevealed a de novo germline mutation of codon 634 in exon 11In a patient with MTC. In addition, somatic mutations of codon918 in exon 16 in six of the remaining MTC: s were found, Interestingly,the presence of this somatic mutation was associated with asignificantly less favorable clinical outcome.     

A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A

Activating germline mutations in the cysteine-rich domain of the RET proto-oncogene are found in >92% of the cases of multiple endocrine neoplasia type 2A (MEN2A) and 85% of familial medullary thyroid carcinoma (FMTC). In virtually 100% of patients with identified mutations one of five cysteines is altered by a missense mutation. In a MEN2A family with 14 affected and 11 unaffected living members, hypercalcemia was diagnosed in eight patients and histological evaluation revealed parathyroid hyperplasia in all cases examined (10/10). No member of this family showed any evidence for the existence of pheochromocytoma. This is the first documentation of a family without pheochromocytoma but with a high incidence of parathyroid disease. Genetic analysis revealed the presence of an unusual heterozygous mutation in exon 11 of the RET proto-oncogene representing a duplication of 12 bp resulting in the insertion of four amino acids between codon 634 (Cys) and 635 (Arg), thus creating an additional cysteine residue.      

Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland.

We investigated the possible role of RET proto-oncogene mutations in the development of sporadic hyperplastic, benign, and malignant parathyroid lesions. DNA extracted from paraffin-embedded specimens of forty parathyroid lesions was screened for RET proto-oncogene point mutations in exons 10, 11, and 16 by nonisotopic polymerase chain reaction-based single-strand conformation polymorphism and heteroduplex gel electrophoresis. The nucleotide sequence of samples with aberrant band patterns was identified by nonisotopic direct sequencing of polymerase chain reaction-amplified DNA. Parathyroids of seven patients with multiple endocrine neoplasia type 2A (MEN 2A) and MEN 2B served as positive controls. None of the eight hyperplastic lesions, three cases of parathyromatosis, ten parathyroid adenomas, eleven carcinomas or one normal parathyroid gland contained mutations in each of the three RET exons tested. Six MEN-2A-associated hyperplastic glands exhibited identical band shifts in the polymerase chain reaction single-strand conformation polymorphism analysis of exon 11, which corresponded to a Cys 634-->Arg substitution in the nucleotide sequence analysis (TGC-->CGC), whereas in the MEN 2B parathyroid specimen a point mutation was found at codon 918 of exon 16 (ATG-->ACG), causing a Met 918-->Thr substitution. Our data indicate that RET mutations of the MEN 2 loci in exons 10, 11, and 16 are not involved in the development of sporadically occurring benign or malignant parathyroid lesions. Furthermore, our results are in accordance with the observation that MEN 2A patients with Cys 634-->Arg (germline) mutations have a higher risk of developing parathyroid disease than those with other mutations at codon 634.     

Genetic aberrance of sporadic MEN 2A component tumours: analysis of RET

AIM: The molecular pathogenesis of familial multiple endocrine neoplasia (MEN) type 2 (parathyroid adenoma with medullary thyroid carcinoma and adrenal pheochromocytoma) is associated with a germ-line mutation in the RET proto-oncogene. We undertook this study to clarify the relationship between the tumorigenesis of apparently sporadic MEN type 2 component endocrine tumours and RET mutations. METHODS: Direct sequencing for RET exon 10, 11, 12, 13, 14, 15 and 16 and immunohistochemistry for RET monoclonal antibody were performed on the archival tissues of 84 cases of sporadic endocrine tumours, including 22 medullary thyroid carcinomas (MTCs), 35 adrenal pheochromocytomas (APCs), 18 paragangliomas (PGs), and nine parathyroid adenomas (PTAs). RESULTS: PCR-based direct sequencing revealed somatic point missense mutation within 22.7% of exon 13 of the RET proto-oncogene (four cases of E768D, one case of S7781) in MTCs. No RET genotype and morphological association was observed in MTCs or APCs. APCs revealed significantly lower levels of immunoexpression of RET, even versus PGs. CONCLUSIONS: The genetic mutation in RET is relatively low in incidence, and likely to play an insignificant role in the molecular pathogenesis of sporadic MTC. The molecular bases of PG and APC seem to be different despite their embryological and histological similarities.     

RET is expressed but not mutated in extra-adrenal paragangliomas

This study has investigated the role of the RET proto-oncogene, which has been identified as the susceptibility gene for multiple endocrine neoplasia (MEN) type 2, in the development of sporadic and familial extra-adrenal paragangliomas. RET protein expression was analysed by immunohistochemistry. Subsequently, DNA extracted from 52 tumours of 44 patients was screened for somatic RET point mutations in exons 10, 11, and 13-16, where oncogenic mutations have recently been described in a subset of sporadic medullary thyroid carcinomas and phaeochromocytomas. The methods employed included non-isotopic polymerase chain reaction-based single strand conformation polymorphism (PCR-SSCP) analysis and heteroduplex gel electrophoresis, followed by direct sequencing of PCR products. RET protein expression was demonstrated in all ten paragangliomas tested. However, none of the familial or sporadic extra-adrenal paragangliomas contained somatic mutations in exons 10, 11, or 13-16 of the RET proto-oncogene, whereas control samples with known mutations in these exons exhibited the expected band shift, or yielded an additional band with retarded migration. Although paragangliomas exhibit RET protein expression, these data indicate that oncogenic RET proto-oncogene mutations do not appear to be generally important in the formation of sporadic paragangliomas.     

RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report

Multiple Endocrine Neoplasia (MEN) 2A is an inherited disease characterized by the development of medullary thyroid carcinoma (MTC), pheochromocytoma(PHCH) and hyperparathyroidism(HPT). It has recently been shown to be associated with germline mutations in the RET proto-oncogene. Genetic testing for RET mutations will, therefore allow the identification of people with asymptomatic MEN 2 who can be offered prophylactic thyroidectomy and biochemical screening as preventive measures. No genetic study based on RET mutation detection has been available in India so far. The aim of the present study is to detect the proportion of MTC cases having inherited germline or somatic RET mutations and to identify family members at risk for MEN and, thereby the feasibility of screening for MEN. DNA extracted from the peripheral blood and somatic (tumor) tissues were subjected to PCR using primers for exons 10,11 and 16. A few samples were subjected to direct sequencing. Germline mutations were identified in 3 of 4 MEN 2A patients, 18 of 24 sporadic MTC(SMTC), 2 of 4 children of MEN2A and 8 relatives of SMTC. Common mutation was in exon 10 and 11 (c634). It is recommended that RET mutation analysis and counseling of patients and their immediate relatives be introduced on a regular basis to identify gene carriers.     

Presymptomatic genetic screening in families with multiple endocrine neoplasia type 2

Medullary thyroid carcinoma occurs sporadically or as a part of the inherited cancer syndrome multiple endocrine neoplasia (MEN) type 2. The MEN 2 gene has been identified as the RET proto-oncogene on chromosome 10. In MEN 2A, RET mutations are detectable in one of five cysteine codons within exons 10 and 11 and in MEN 2B in codon 918 (exon 16). Direct DNA testing for RET proto-oncogene mutations is the method of first choice in presymptomatic screening of MEN 2 families. Gene carriers should be offered prophylactic thyroidectomy. The process of DNA analysis for RET proto-oncogene mutations is demonstrated in one family with hereditary medullary thyroid carcinoma. RET mutations were detectable in five of the nine family members at risk.Abbreviations MEN Multiple endocrine neoplasia - MTC Medullary thyroid carcinoma - FMTC Familial medullary thyroid carcinoma - PCR Polymerase chain reaction - C-cells Calcitonin-producing parafollicular cells     

First continuous human pheochromocytoma cell line: KNA. Biological, cytogenetic and molecular characterization of KNA cells

Pheochromocytomas are rare tumours, with an incidence of 1–2 per million which arise from chromaffin cells of the adrenal medulla. They occur sporadically or as part of dominantly inherited cancer syndromes like multiple endocrine neoplasia 2 (MEN2A and 2B) and others. Continuous cell lines, not available so far, are essential tools for studies in these tumours. A continuous cell line (KNA) was established from a sporadic pheochromocytoma of the right adrenal gland of a 73-year-old woman. The KNA cells grow as suspensions of spheroids and show the morphological and immunocytochemical characteristics of neuronal chromaffin cells, such as neuroendocrine granules, and positive reactions to chromogranin- and related peptide-, neuron specific enolase and vasoactive intestinal peptide antibodies. Neurite-like processes are formed after addition of nerve growth factor. Chromosomal analyses revealed a diploid (46,XX, n=50) to hypodiploid (43–45,XX, n=15) karyotype. In hypodiploid metaphases most frequently #19, #17, #21 and #22 were missing. Chromosome arms 1p and 4q showed apparently consistent interstitial deletions: 6q, 8q, 13q and 22q showed clonal interstitial deletions. The cell line shows a heterozygous sequence variant TGC (cysteine) to TGG (tryptophan) in codon 611 in exon 10 of the RET proto-oncogene. So far, PC-12, a rat adrenal pheochromocytoma, has been the only continuous pheochromocytoma cell line available. KNA represents the first report on a human continuous pheochromocytoma cell line, the first report of structural chromosome aberrations in pheochromocytomas and the first report of a RET mutation TGC to TGG in exon 10 of the RET proto-oncogene in a sporadic pheochromocytoma. © 1998 Chapman and Hall     

Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression

Hirschsprung disease (HSCR) is a common genetic disorder presenting with functional intestinal obstruction secondary to enteric aganglionosis. HSCR can be familial or sporadic. Although five putative susceptibility genes have been identified, only germline mutations in the RET proto-oncogene account for a significant minority (up to 50%) of familial HSCR; 3% of sporadic HSCR in a population based series carry RET mutations. From 1998 to February 1999, we prospectively ascertained 64 cases of sporadic HSCR from the western Andalusia region. To determine if polymorphic sequence variants within RET could act as low penetrance predisposing alleles, we examined allelic frequencies at seven polymorphic loci in this population based series. Whether allele frequencies differed from those in the control population were determined by either chi-squared analysis or Fisher's exact test. For two sequence variants, A45A (c 135G-->A) (exon 2) and L769L (c 2307T-->G) (exon 13), the rarer polymorphic allele was over-represented among HSCR cases versus controls (p<0.0006). In contrast, two other polymorphisms, G691S (c 2071C-->A) (exon 11) and S904S (c 2712C-->G) (exon 15), were under-represented in the HSCR patients compared to controls (p=0.02). Polymorphisms in the RET proto-oncogene appear to predispose to HSCR in a complex, low penetrance fashion and may also modify phenotypic expression.